Solid Balance SheetMedicamen's balance sheet shows moderate leverage, a solid equity ratio and satisfactory ROE, indicating long‑term solvency and capital efficiency. This durable financial structure supports investment, absorbs industry shocks, and preserves access to financing over the next several quarters.

Healthy Operating MarginsRelatively strong EBIT/EBITDA margins signal consistent operational efficiency in manufacturing finished dosage forms. Sustainable margins provide cash available for reinvestment and buffer against pricing pressure in generics, helping preserve profitability over a multi‑quarter horizon.

Diversified Revenue ChannelsMedicamen generates sales from both domestic formulation channels and exports, giving geographic and customer diversification. This business model reduces reliance on any single market, supports scale in manufacturing, and allows capture of global demand trends for finished dosage forms over time.

Bears Say

Negative Cash ConversionPersistent negative operating and free cash flow indicate the company struggles to turn accounting profits into cash. Over 2–6 months this constrains capital expenditure, working capital flexibility and ability to fund growth internally, raising refinancing and liquidity risk if unresolved.

Revenue InconsistencyFluctuating top‑line and volatile net margins undermine predictability of earnings and cash flow. For a manufacturer of finished dosages, inconsistent demand or pricing squeezes long‑term planning, weakens bargaining power with suppliers, and complicates sustainable margin management.

Recent Revenue DeclineA roughly 7.5% revenue decline signals near‑term demand headwinds or loss of market share. If the trend persists, it reduces operating leverage, presses margins, and limits reinvestment capacity, which could exacerbate cash flow stress and impair strategic initiatives over several quarters.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

22d ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹269.40 and its highest was ₹545.20 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹3.72B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Jun 03, 2026 which is in 80 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Feb 13, 2026. The company reported ₹1.613 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.613.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.26%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.613 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.671%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.